$GMED

ZARRILLI STEPHEN T sold $2.2M of GMED

ZARRILLI STEPHEN T sold 25,000 shares of GLOBUS MEDICAL INC (GMED) at $87.04 ($2.18M total) on 2026-08-18.

Original reporting
SEC EDGAR · ZARRILLI STEPHEN T
Published Aug 19, 2026, 9:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 9:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GMED
Neutral
medium confidence
Mentioned
$GMED
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GMEDNeutralLow
01

Why it matters

The sale reduces insider ownership to zero, which may affect perception of insider alignment with shareholders.

02

Market read

Insider sell of $2.2M may cause slight price dip but unlikely to trigger major market moves.

03

What to watch

Potential tax planning or personal liquidity needs may drive the transaction.

Relevance 6/10Novelty 7/10Timing: filing disclosed today

Background

Form 4 filings disclose insider transactions; a director's complete exit is noteworthy.

Company-level read

Ticker impact

$GMEDNeutralMedium confidence
Context

Director Stephen Zarrilli sold 25,000 shares for $2.18M, reducing his stake to zero.

Expected impact

Potential slight downward pressure, likely within normal volatility range.

Evidence & confidence

A $2.2M sale by a director is notable but not large enough to drive a significant move; market may view it as routine portfolio rebalancing.

Market effects

Minimal impact on the medical device sector.

No broader regional effect.

Limited to investors tracking insider activity.

Counterpoint

The sale could be unrelated to company outlook; insiders often diversify holdings.

Key entities

  • Globus Medical Inc

    Medical device manufacturer listed on NASDAQ (GMED).

  • Stephen Zarrilli

    Director of Globus Medical who sold his entire stake.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GMEDMedAI 8/10

Audubon's Globus Medical Brings Its 3-in-1 Surgical Imaging System to European Union

Globus Medical (GMED) announced its Excelsius3D imaging system received CE marking, allowing sales in the EU and UK. The system combines 3D cone-beam CT, 2D fluoroscopy, and digital radiography for surgical use. CEO Keith Pfeil highlighted the milestone's importance for the Excelsius Ecosystem. The company has been active in M&A and product development, including acquiring Higgs Boson Health and Nevro.

$GMEDMedAI 8/10

What Does Globus Medical (GMED) CE Mark Approval Mean For Its Europe Launch?

Globus Medical (GMED) received CE Mark approval for its Excelsius3D imaging system, allowing its commercial launch in the EU and UK. The approval expands the company's Excelsius platform into new markets, supporting advanced surgical procedures. Globus Medical, with a market cap of $10.5b, aims to integrate robotics, imaging, and implants for higher margins in spine and orthopaedic care.

$GMEDMedAI 8/10

Globus Medical wins CE mark for Excelsius3D imaging system

Globus Medical (GMED) received CE mark for its Excelsius3D imaging system for spine and cranial procedures, enabling EU/UK commercialization. The system combines 3D CT, 2D fluoroscopy, and digital radiography, integrating with the ExcelsiusGPS robotic navigation system. According to the company, this expands its Excelsius ecosystem in Europe.

$GMEDHighAI 9/10

Globus Medical (GMED) Received CE Mark For Its Excelsius3D Imaging System

Globus Medical (GMED) received CE marking for its Excelsius3D imaging system, allowing commercial launch in the EU and UK. The system is part of the company's imaging and navigation platform for spine and orthopedic procedures. Globus Medical has a market cap of approximately $10.8 billion. The approval supports the company's strategy in surgical imaging and guidance platforms, potentially contributing to earnings and margin expansion.